We represented a Fortune 500 company in the life sciences industry in an investigation by the U.S. Department of Justice and Securities and Exchange Commission of alleged FCPA and local law violations relating to the company’s operations in Europe and conduct of its distributors. This representation included providing guidance and advice about the pros and cons of self-reporting, the potential value of cooperation, and benefits of remedial actions taken to enhance the existing compliance program.
Investigation of FCPA Violations in Europe
You Also May Be Interested In:
Representation of Lineagen, Inc., a provider of molecular diagnostics services for individuals showing clinical presentations consistent with neurodevelopmental disorders, in its sale to Bionano Genomics, Inc. (Nasdaq: BNGO), a genome analysis company providing tools and services to scientists and clinicians conducting genetic research and patient testing, for $9.6 million
Served as regulatory and deal counsel to BioPlus, a leading national specialty pharmacy, and ProHealth Pharmacy Solutions, a significant provider of infusion pharmacy management services in their sale to CarepathRx a platform company formed by Nautic Partners
Representation of Lincare Holdings, Inc., a nationwide healthcare services organization and a Florida-based subsidiary of German multinational chemical company Linde AG, in its sale of their home infusion assets to KabaFusion, a provider of specialty acute and chronic home infusion therapies